Resmetirom (Rezdiffra™)
MASH with moderate to advanced fibrosis (F2-F3)
Key Facts
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals' mission is to deliver novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet need. The company's landmark achievement is the U.S. and EU approval of resmetirom, the first-ever therapy for MASH with significant fibrosis, stemming from its pioneering work on thyroid hormone receptor-beta agonism. Madrigal's strategy involves building a fully integrated commercial biopharma company to capture the immense MASH market opportunity while advancing its clinical pipeline into additional liver and metabolic disorders. This positions Madrigal as the definitive first-mover in a multi-billion dollar therapeutic arena.
View full company profile